Table 3.
Parameter | Ceftazidime | Piperacillin | Meropenem 3 g/d | Meropenem 6 g/d | Linezolid |
---|---|---|---|---|---|
ECMO | 0.69 | 0.029a | 0.02a | 0.372 | 0.618 |
ECMOF24 | 0.15 | 0.63 | 0.86 | 0.48 | 0.19 |
Duration of use of ECMO membrane oxygenator (days) | 0.006b | 0.84 | 0.014b | 0.23 | < 0.05b |
CRRT | 0.03a | < 0.05b | 0.01b | 0.36 | 0.44 |
CRRT BF24 | – | 0.556 | 0.22 | < 0.05a | 0.132 |
CRRT DF24 | – | 0.2 | 0.82 | 0.01a | 0.731 |
Italic values indicate multiple linear generalized estimating equation (GEE) analyses were used and a p value below 0.05 was considered as statistically significant
The analysis was adjusted for age, sex, body mass index and renal function (expressed as estimated creatine clearance using the CKD-EPI formula). Of note, an average of 3.55 serial measurements of antibiotic serum concentrations were performed per patient (range: 1–14)
ECMO extracorporeal membrane oxygenation, ECMOF24 mean ECMO flow in l/min during 24 h, CRRT continuous renal replacement therapy, CRRT BF24 mean CRRT blood flow in ml/min during 24 h, CRRT DF24 mean CRRT dialysate flow in ml/h during 24 h
aAssociated with a decreased antibiotic serum concentration
bAssociated with an elevated antibiotic serum concentration